Literature DB >> 3927795

Spinal cord injury and protection.

D K Anderson, P Demediuk, R D Saunders, L L Dugan, E D Means, L A Horrocks.   

Abstract

Subsequent to traumatic injury of the spinal cord, a series of pathophysiological events occurs in the injured tissue that leads to tissue destruction and paraplegia. These include hemorrhagic necrosis, ischemia, edema, inflammation, neuronophagia, loss of Ca2+ from the extracellular space, and loss of K+ from the intracellular space. In addition, there is trauma-initiated lipid peroxidation and hydrolysis in cellular membranes. Both lipid peroxidation and hydrolysis can damage cells directly; hydrolysis also results in the formation of the biologically active prostaglandins and leukotrienes (eicosanoids). The time course of membrane lipid alterations seen in studies of antioxidant interventions suggests that posttraumatic ischemia, edema, inflammation, and ionic fluxes are the result of extensive membrane peroxidative reactions and lipolysis that produce vasoactive and chemotactic eicosanoids. A diverse group of compounds has been shown to be effective in ameliorating spinal cord injury in experimental animals. These include the synthetic glucocorticoid methylprednisolone sodium succinate (MPSS); the antioxidants vitamin E, selenium, and dimethyl sulfoxide (DMSO); the opiate antagonist naloxone; and thyrotropin-releasing hormone (TRH). With the exception of TRH, all of these agents have demonstrable antioxidant and/or anti-lipid-hydrolysis properties. Thus the effectiveness of these substances may lie in their ability to quench membrane peroxidative reactions or to inhibit the release of fatty acids from membrane phospholipids, or both. Whatever the mode of action, early administration appears to be a requirement for maximum effectiveness.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3927795     DOI: 10.1016/s0196-0644(85)80064-0

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  8 in total

Review 1.  Active oxygen in neuromuscular disorders.

Authors:  A Davison; G Tibbits; Z G Shi; J Moon
Journal:  Mol Cell Biochem       Date:  1988-12       Impact factor: 3.396

2.  The antioxidant effect of beta-Glucan on oxidative stress status in experimental spinal cord injury in rats.

Authors:  Hakan Kayali; M Fatih Ozdag; Serdar Kahraman; Ahmet Aydin; Engin Gonul; Ahmet Sayal; Zeki Odabasi; Erdener Timurkaynak
Journal:  Neurosurg Rev       Date:  2005-04-30       Impact factor: 3.042

3.  Hemoglobin potentiates central nervous system damage.

Authors:  S M Sadrzadeh; D K Anderson; S S Panter; P E Hallaway; J W Eaton
Journal:  J Clin Invest       Date:  1987-02       Impact factor: 14.808

4.  The effect of duration of compression on lipid peroxidation after experimental spinal cord injury.

Authors:  M Y Kaynar; M Hanci; A Kafadar; K Gümüştaş; A Belce; N Ciplak
Journal:  Neurosurg Rev       Date:  1998       Impact factor: 3.042

5.  Key role for pregnenolone in combination therapy that promotes recovery after spinal cord injury.

Authors:  L Guth; Z Zhang; E Roberts
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-06       Impact factor: 11.205

6.  Effects of mexiletine, ginkgo biloba extract (EGb 761), and their combination on experimental head injury.

Authors:  Ahmet Menkü; R Kemal Koç; Vatan Tayfur; Recep Saraymen; Figen Narin; Hidayet Akdemir
Journal:  Neurosurg Rev       Date:  2003-07-12       Impact factor: 3.042

7.  Erythropoietin exerts neuroprotection after acute spinal cord injury in rats: effect on lipid peroxidation and early ultrastructural findings.

Authors:  Erkan Kaptanoglu; Ihsan Solaroglu; Ozerk Okutan; H Selcuk Surucu; Filiz Akbiyik; Etem Beskonakli
Journal:  Neurosurg Rev       Date:  2003-08-14       Impact factor: 3.042

8.  Randomized clinical trial comparing outcomes after fentanyl or ketamine-dexmedetomidine analgesia in thoracolumbar spinal surgery in dogs.

Authors:  Stephanie Lovell; Bradley Simon; Elizabeth C Boudreau; Joseph Mankin; Nicholas Jeffery
Journal:  J Vet Intern Med       Date:  2022-08-13       Impact factor: 3.175

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.